Download PDF
Fortschr Neurol Psychiatr 2005; 73(10): 577-586
DOI: 10.1055/s-2004-830283
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Neurologische Manifestationen der HIV-Infektion in der Ära der hochaktiven antiretroviralen Therapie (HAART)

Neurological Manifestations of HIV-Infection in the Era of Highly Active Antiretroviral Therapy (HAART)G.  Arendt1
  • 1Neurologische Klinik des Universitätsklinikums Düsseldorf (UKD) (Direktor: Professor Dr. H.-P. Hartung)
Further Information

Publication History

Publication Date:
20 June 2005 (online)

    Permissions and Reprints

Zusammenfassung

Die neurologischen System-Manifestationen der HIV-Infektion haben sich nach Einführung der antiretroviralen Therapie 1996 nicht wie die extranervalen Komplikationen zurückgebildet, sondern nehmen in den letzten Jahren - wie internationale Studien ausweisen - relativ gesehen - wieder zu. Der klinisch und in der ambulanten Versorgung tätige Arzt sollte daher diese Krankheitsbilder - auch in ihren Frühstadien - erkennen können. Der vorliegende Artikel beschreibt Symptome sowie bildgebungs- und liquortechnische Diagnostik und die Therapie primär HIV-1-assoziierter Erkrankungen wie der Enzephalo- und Myelopathie und der Polyneuropathien. Ferner werden diejenigen opportunistischen Erkrankungen, Infektionen durch Bakterien, Viren und Parasiten, die bei manifester Immunschwäche auftreten und heutzutage noch von zahlenmäßiger Relevanz sind, nach diagnostischen, differenzialdiagnostischen und therapeutischen Gesichtspunkten dargestellt. Ein gesonderter Abschnitt ist der hochaktiven, antiretroviralen Therapie (HAART) und ihren Interaktionen mit neurologisch/psychiatrischen Standardtherapien gewidmet.

Abstract

After the introduction of highly active antiretroviral therapy (HAART) in 1996 the neurological manifestations of human immunodeficiency virus (HIV-1)-infection did not decline in incidence and prevalence like the other complications of immunodeficiency; in contrast, due to the longer survival times of HAART treated HIV-1-positive individuals, prevalence of virus associated neurological disease increased during the last years, as international studies underline. Therefore, clinicians and HIV-therapists should be able to diagnose HIV-1-associated neurological disease even in early stages. This article describes symptoms and signs, neuro-imaging and cerebrospinal fluid findings as well as therapy options in primary HIV-1-associated neurological disease like encephalo- and myelopathy and polyneuropathy. Furthermore, those opportunistic infections, caused by bacteria, viruses other than HIV and parasites emerging with manifest immunodeficiency and remaining to be relevant in the HAART era are presented from diagnostic, differential-diagnostic and therapeutic points of view. An extra paragraph describes the interaction of HAART with neurological/psychiatric standard therapies.

Literatur

  • 1 Dore G J, Correll P K, Li Y, Kaldor J M, Cooper D A, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.  Aids. 1999;  13 1249-1253
    PubMedGoogle Scholar
  • 2 Dore G J, McDonald A, Li Y, Kaldor J M, Brew B J,. National HIV Surveillance Committee . Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.  AIDS. 2003;  17 1539-1545
    CrossrefPubMedGoogle Scholar
  • 3 Eggers C. HIV-1 associated encephalopathy and myelopathy.  J Neurol. 2002;  249 1132-1136
    CrossrefPubMedGoogle Scholar
  • 4 Arendt G, Hefter H, Elsing C, Neuen J E, Strohmeyer G, Freund H J. Neue elektrophysiologische Befunde zur Häufigkeit der Gehirnbeteiligung bei klinisch-neurologisch asymptomatischen HIV-Infizierten (New electrophysiological findings on the incidence of brain involvement in clinically and neurologically asymptomatic HIV infections).  Zeitschrift für Elektroenzephalographie, Elektromyographie und verwandte Gebiete. 1989;  20 280-287
    PubMedGoogle Scholar
  • 5 Arendt G, Hefter H, Elsing C, Strohmeyer G, Freund H J. Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit.  Journal of Neurology. 1990;  237 362-368
    CrossrefPubMedGoogle Scholar
  • 6 Arendt G, Hefter H, Hilperath F, Giesen H J von, Strohmeyer G, Freund H J. Motor analysis predicts progression in HIV-associated brain disease.  Journal of the Neurological Sciences. 1994;  123 180-185
    CrossrefPubMedGoogle Scholar
  • 7 Arendt G. Die Bedeutung quantifizierender elektrophysiologischer Parameter für die Erfassung der Verlaufskinetik HIV assoziierter zerebraler Erkrankungen. 1994
    Google Scholar
  • 8 Schmitt F A, Bigley J W, McKinnis R, Logue P E, Evans R W, Drucker J L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.  N Engl J Med. 1988;  319 1573-1578
    PubMedGoogle Scholar
  • 9 Arendt G, Hefter H, Buescher L, Hilperath F, Elsing C, Freund H J. Improvement of motor performance of HIV-positive patients under AZT therapy.  Neurology. 1992;  42 891-896
    PubMedGoogle Scholar
  • 10 Janssen R S, Cornblath D R, Epstein L G, Foa R P, McArthur J C, Price R W, Asbury A K, Beckett A, Benson D F, Bridge T P, Leventhal C M, Satz P, Saykin A J, Sidtis J J, Tross S. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection.  Neurology. 1991;  41 778-785
    PubMedGoogle Scholar
  • 11 Berger J R, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems.  J Psychopharmacol. 2000;  14 214-221
    PubMedGoogle Scholar
  • 12 Berger J R, Nath A. HIV dementia and the basal ganglia.  Intervirology. 1997;  40 122-131
    PubMedGoogle Scholar
  • 13 Chuang H T, Devins G M, Hunsley J, Gill J M. Psychosocial Distress and Well-Being Among Gay and Bisexual Men With Human Immunodeficiency Virus Infection.  American Journal of Psychiatry. 1989;  146 876-880
    PubMedGoogle Scholar
  • 14 Neuen-Jacob E, Arendt G, Wendtland B, Jacob B, Schneeweis M, Wechsler W. Frequency and topographical distribution of CD68-positive macrophages and HIV-1 core proteins in HIV-associated brain lesions.  Clin Neuropathol. 1993;  12 315-324
    PubMedGoogle Scholar
  • 15 Wenserski F, Giesen H J von, Wittsack H J, Aulich A, Arendt G. Human Immunodeficiency Virus 1-associated Minor Motor Disorders: Perfusion-weighted MR Imaging and H MR Spectroscopy.  Neuroradiology. 2003;  228 185-192
    PubMedGoogle Scholar
  • 16 Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, Walot I, Miller E N. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.  Neurology. 1999;  53 782-789
    CrossrefPubMedGoogle Scholar
  • 17 Giesen H J von, Antke C, Hefter H, Wenserski F, Seitz R J, Arendt G. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings.  Arch Neurol. 2000;  57 1601-1607
    CrossrefPubMedGoogle Scholar
  • 18 Ellis R J, Hsia K, Spector S A, Nelson J A, Heaton R K, Wallace M R, Abramson I, Atkinson J H, Grant I, McCutchan J A. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.  Ann Neurol. 1997;  42 679-688
    CrossrefPubMedGoogle Scholar
  • 19 Ellis R J. HIV dynamics in cerebrospinal fluid (CSF) after antiretroviral therapy initiation and interruption.  J Neurovirol. 2002;  8 (suppl 1) 1-51
    PubMedGoogle Scholar
  • 20 Gisslen M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.  J Acquir Immune Defic Syndr Hum Retrovirol. 1998;  17 291-295
    PubMedGoogle Scholar
  • 21 Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load intrathecal immunoactivation and cerebrospinal fluid monocytic cell count in HIV-1 infection.  J Acquir Immune Defic Syndr. 1999;  21 271-276
    CrossrefPubMedGoogle Scholar
  • 22 Lipton S A, Yeh M, Dreyer E B. Update on current models of HIV-related neuronal injury: platelet-activating factor, arachidonic acid and nitric oxide.  Adv Neuroimmunol. 1994;  4 181-188
    PubMedGoogle Scholar
  • 23 Lipton S A. Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species.  Brain Pathol. 1996;  6 507-517
    PubMedGoogle Scholar
  • 24 Kaul M, Garden G A, Lipton S A. Pathways to neuronal injury and apoptosis in HIV-associated dementia.  Nature. 2001;  410 988-994
    CrossrefPubMedGoogle Scholar
  • 25 Lipton S A. HIV-associated neural injury and apoptosis: excitotoxins chemokines and caspases.  J Neurovirol. 2002;  8 (suppl 1) 41
    PubMedGoogle Scholar
  • 26 Köller H, Schaal H, Giesen H J von, Arendt G. TNF-a and gp 120 induced astroglial dysfunction - implications for HIV-1 associated encephalopathy.  J Neurovirol. 2002;  8 (suppl 1) 41
    PubMedGoogle Scholar
  • 27 Köller H, Schaal H, Rosenbaum C, Giesen H J von, Müller H W, Arendt G. CXCR4 receptor mediated HIV-1 gp120-induced intracellular calcium dysregulation in cultured rat cortical astrocytes.  J Neurovirol. 2002;  8 (suppl 1) 9
    PubMedGoogle Scholar
  • 28 Mayne M, Bratanich A C, Chen P, Rana F, Nath A, Power C. HIV-1 tat molecular diversity and induction of TNF-alpha: implications for HIV-induced neurological disease.  Neuroimmunomodulation. 1998;  5 184-192
    CrossrefPubMedGoogle Scholar
  • 29 Nath A. Pathobiology of human immunodeficiency virus dementia.  Semin Neurol. 1999;  19 113-127
    PubMedGoogle Scholar
  • 30 Toborek M, Pu H, Flora G, Lee Y W, Hennig B, Nath A. The HIV protein Tat-induced induction of inflammatory responses in the brain tissue.  J Neurovirol. 2002;  8 (suppl 1) 43
    PubMedGoogle Scholar
  • 31 Giesen H J von, Köller H, Theisen A, Arendt G. Therapeutic Effects of Nonnucleoside Reverse Transcriptase Inhibitors on the Central Nervous System in HIV-1-Infected Patients.  J Acquir Immune Defic Syndr. 2002;  29 363-367
    PubMedGoogle Scholar
  • 32 Arendt G, Giesen H J von, Hefter H, Theisen A. Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.  AIDS. 2001;  15 493-500
    PubMedGoogle Scholar
  • 33 Portegies P. HIV-1, the brain and combination therapy.  The Lancet. 1995;  346 1244-1245
    CrossrefPubMedGoogle Scholar
  • 34 Tyor W R, Wesselingh S L, Griffin J W, McArthur J C, Griffin D E. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy and sensory neuropathy.  J Acquir Immune Defic Syndr Hum Retrovirol. 1995;  9 379-388
    PubMedGoogle Scholar
  • 35 Simpson D M, Wolfe D E. Neuromuscular complications of HIV infection and its treatment.  AIDS. 1991;  5 917-926
    PubMedGoogle Scholar
  • 36 McArthur J C, Yiannoutsos C, Simpson D M, Adornato B T, Singer E J, Hollander H, Marra C, Rubin M, Cohen B A, Tucker T, Navia B A, Schifitto G, Katzenstein D, Rask C, Zaborski L, Smith M E, Shriver S, Millar L, Clifford D B. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291 [In Process Citation].  Neurology. 2000;  54 1080-1088
    CrossrefPubMedGoogle Scholar
  • 37 Berger J R, Simpson D M. The pathogenesis of diffuse infiltrative lymphocytosis syndrome: an AIDS-related peripheral neuropathy [editorial; comment].  Neurology. 1998;  50 855-857
    PubMedGoogle Scholar
  • 38 Moulignier A, Authier F J, Baudrimont M, Pialoux G, Belec L, Polivka M, Clair B, Gray F, Mikol J, Gherardi R K. Peripheral neuropathy in Human Immunodeficiency Virus-infected patients with the diffuse infiltrative lymphocytosis syndrome.  Annals of Neurology. 1997;  41 438-445
    CrossrefPubMedGoogle Scholar
  • 39 Gherardi R K, Chretien F, Delfau-Larue M H, Authier F J, Moulignier A, Roulland-Dussoix D, Belec L. Neuropathy in diffuse infiltrative lymphocytosis syndrome: an HIV neuropathy, not a lymphoma [see comments].  Neurology. 1998;  50 1041-1044
    CrossrefPubMedGoogle Scholar
  • 40 Anders H J, Goebel F D. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome.  Int J STD AIDS. 1999;  10 151-159 quiz 160-161
    CrossrefPubMedGoogle Scholar
  • 41 Simpson D M, Tagliati M. Nucleoside Analogue-Associated Peripheral Neuropathy in Human Immunodeficiency Virus Infection.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995;  9 153-161
    PubMedGoogle Scholar
  • 42 Simpson D. Peripheral neuropathies associated with HIV and antiretroviral therapies.  J Neurovirol. 2002;  8 (suppl 1) 3
    PubMedGoogle Scholar
  • 43 Berger A R, Arezzo J C, Schaumburg H H, Skowron G, Merigan T, Bozette S, Richman D, Soo W. 2,3′-Dideoxycytidine (ddC) toxic neuropathy.  Neurology. 1993;  43 358-362
    PubMedGoogle Scholar
  • 44 Arendt G, Giesen H-J von. Klinik, Pathogenese und Therapie von Neuro-AIDS. Bremen, London, Boston: Uni-Med Verlag AG 2000
    Google Scholar
  • 45 Giesen H J von, Hefter H, Jablonowski H, Arendt G. Stavudine (2,3′-Didehydro-3′deoxythymidine; D4T) and the peripheral nerve in HIV-1-infected patients.  Journal of Neurology. 1999;  246 211-217
    CrossrefPubMedGoogle Scholar
  • 46 Dalakas M C, Pezeshkpour G H. Neuromuscular diseases associated with Human Immunodeficiency Virus infection.  Ann Neurol. 1988;  23 (Suppl) S38-S48
    CrossrefPubMedGoogle Scholar
  • 47 Dalakas M C, Illa I, Pezeshkpour G H, Laukaitis J P, Cohen B, Griffin J L. Mitochondrial myopathy caused by long-term zidovudine therapy [see comments].  N Engl J Med. 1990;  322 1098-1105
    PubMedGoogle Scholar
  • 48 Cupler E J, Leon-Monzon M, Miller J, Semino-Mora C, Anderson T L, Dalakas M C. Inclusion body myositis in HIV-1 and HTLV-1 infected patients.  Brain. 1996;  119 1887-1893
    PubMedGoogle Scholar
  • 49 Gertner E, Thurn J R, Williams D N, Simpson M, Balfour Jr H H, Rhame F, Henry K. Zidovudine-associated myopathy.  Am J Med. 1989;  86 814-818
    CrossrefPubMedGoogle Scholar
  • 50 Simpson D M, Slasor P, Dafni U, Berger J, Fischl M A, Hall C. Analysis of myopathy in a placebo-controlled zidovudine trial.  Muscle Nerve. 1997;  20 382-385
    PubMedGoogle Scholar
  • 51 Pezeshkpour G, Illa I, Dalakas M C. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.  Hum Pathol. 1991;  22 1281-1288
    CrossrefPubMedGoogle Scholar
  • 52 DNAA . Aktuelle Diagnostik und Therapie opportunistischer Hirnerkrankungen bei AIDS.  Dtsch Med Wochenschr. 2002;  127 1479-1485
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Bossi P, Caumes E, Astagneau P, Li T S, Paris L, Mengual X, Katlama C, Bricaire F. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].  Rev Med Interne. 1998;  19 313-317
    PubMedGoogle Scholar
  • 54 Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla A M, Luke W, Lazzarin A, Weber T, Cinque P. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response [In Process Citation].  Clin Infect Dis. 2000;  30 95-99
    CrossrefPubMedGoogle Scholar
  • 55 Weber T, Turner R W, Frye S, Luke W, Kretzschmar H A, Luer W, Hunsmann G. Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid.  Aids. 1994;  8 49-57
    PubMedGoogle Scholar
  • 56 Giesen H J von, Neuen-Jacob E, Dörries K, Jablonowski H, Roick H, Arendt G. Diagnostic criteria and clinical procedures in HIV-1-associated progressive multifocal leukoencephalopathy.  Journal of Neurological Sciences. 1997;  147 63-72
    CrossrefPubMedGoogle Scholar
  • 57 Arendt G. DNAA f. d. D.N.A.A . Antiretrovirale Therapie - Strategien aus Sicht des Neurologen.  Deutsches Ärzteblatt. 2000;  97 B-831-B-832
    PubMedGoogle Scholar

Prof. Dr. Gabriele Arendt

Neurologische Klinik des Universitätsklinikums Düsseldorf (UKD)

Moorenstr 5

40225 Düsseldorf

Email: Gabriele.Arendt@uni-duesseldorf.de

      >